| |
4 HCV Cost-Effectiveness Studies Just Published; Costs for New Cancer/Cholesterol, Diabetes Drugs - New Model to Fund Healthcare
|
| |
| |
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus - (03/18/15) .....17 March 2015 Ann Intern Med....Mehdi Najafzadeh, PhD; Karin Andersson, MD; William H. Shrank, MD, MSHS; Alexis A. Krumme, MS; Olga S. Matlin, PhD; Troyen Brennan, MD, JD, MPH; Jerry Avorn, MD; and Niteesh K. Choudhry, MD, PhD. From Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, and Massachusetts General Hospital, Boston, Massachusetts, and CVS Health, Woonsocket, Rhode Island.
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States - (03/18/15).....17 March 2015 Ann Intern Med......Jagpreet Chhatwal, PhD; Fasiha Kanwal, MD, MSHS; Mark S. Roberts, MD, MPP; and Michael A. Dunn, MD.....From the University of Texas MD Anderson Cancer Center, Baylor College of Medicine, Houston Veterans Affairs Health Services Research and Development Center of Excellence, and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, and University of Pittsburgh Graduate School of Public Health and University of Pittsburgh, Pittsburgh, Pennsylvania
from Jules: note - "The weekly costs of sofosbuvir and ledipasvir were $7000 and $875, respectively" this is in Methods section, $7k is at the 84k price
Medical Costs
The model was developed from a third-party payer perspective. All costs were converted to a 2014 baseline by using the Consumer Price Index (51). The weekly costs of sofosbuvir and ledipasvir were $7000 and $875, respectively (52). The weekly costs of peginterferon, ribavirin, boceprevir, and telaprevir were $587, $309, $1100, and $4100, respectively (52). Because most payers receive discounts, we applied the average discount of 11% to all drugs (Supplement). We used our previously published study to estimate health state-specific annual costs (22, 53).
NYS DURB Mtg Feb 26 Viekira Pak Declared Preferred Drug for FFS Medicaid - Summary/Video - (03/16/15)
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease - (03/16/15) .....Hepatology.....ndrew J. Leidnera Harrell W. Chessonb Fujie Xua John W. Warda Philip R. Spradlinga Scott D. Holmberga
Affiliation: a. Division of Viral Hepatitis Centers for Disease Control and Prevention b. Division of Sexually Transmitted Disease Prevention Centers for Disease Control and Prevention
The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus and Editorial - (03/16/15)
Expensive Cancer, Heart Disease, Diabetes Drugs over the long run more expensive than HCV - (03/16/15) ......PCSK9 inhibitors will be prescribed as ongoing maintenance therapy for the duration of patients' lives.......injectable cholesterol treatments.....PCSK9 inhibitors .....belong to an experimental class of medicines.....cost $7,000 to $12,000 a year and patients could be on them for life.....Private payers and government officials are spooked by the prospect of treating some 3 million patients infected with hepatitis C, at some $100,000 a shot, Express Scripts CMO Steve Miller said at a recent conference. So should they be about the PCSK9 class. "[T]hink about a lifetime drug that's probably going to cost greater than $10,000 annually times 71 million people......new cancer medicines as well as innovative drugs for other diseases coming to market,......Half of the about 30 cancer drugs introduced since 2010 cost $10,000 a month or more and all were at least $5,000 a month,......new class of cancer drugs, called PD-1 inhibitors, on the market for melanoma...... cost about $150,000 a year and are expected to be widely used.....inflammatory conditions, multiple sclerosis and cancer......inflammatory conditions, such as rheumatoid arthritis and Crohn's disease......entral nervous system disorders, which includes treatments for Huntington's disease, narcolepsy and Parkinson's disease.....Diabetes, high blood pressure and high blood cholesterol accounted for more than a quarter of total Part D spending......The costliest specialty condition for Part D in 2013 was cancer, followed by multiple sclerosis and inflammatory conditions Eight of the newly approved drugs during the past two years were for diabetes, including four last year: Farxiga (in January), Tanzeum (in April), Jardiance (in August), and Trulicity (in September). Those approvals followed FDA approvals in 2013 for Invokana, Kazano, Nesina, and Oseni.
New Models for Healthcare Funding Needed - (08/06/14)
|
|
| |
| |
|
|
|
